Evidence map›Paper›PMID 38706901›Full record

ArticleJournal of Cancer2024

Angiogenesis-related lncRNAs index: A predictor for CESC prognosis, immunotherapy efficacy, and chemosensitivity.

Xueyuan Huang, Guangming Yi, Jiayu Xu, Siqi Gou, Haiqing Chen, Xiaoyan Chen, Xiaomin Quan, Linjia Xie, Alexander Tobias Teichmann, Guanhu Yang and 2 more

Abstract read
In one paragraph

Article in Journal of Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xueyuan HuangClinical Medical College, Southwest Medical University, Luzhou 646000, China.
Guangming YiDepartment of Oncology, The Third Hospital of Mianyang (Sichuan Mental Health Center), Mianyang, Sichuan 621000, China.
Jiayu XuSchool of Science, Minzu University of China, Beijing 100081, China.
Siqi GouClinical Medical College, Southwest Medical University, Luzhou 646000, China.
Haiqing ChenClinical Medical College, Southwest Medical University, Luzhou 646000, China.
Xiaoyan ChenDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Wenzhou Medical University, China.
Xiaomin QuanBeijing University of Chinese Medicine, 100029, Beijing, China.
Linjia XieClinical Medical College, Southwest Medical University, Luzhou 646000, China.
Alexander Tobias TeichmannSichuan Provincial Center for Gynecology and Breast Diseases (Gynecology), Affiliated Hospital of Southwest Medical University, Luzhou 646000, China.
Guanhu YangDepartment of Specialty Medicine, Ohio University, Athens 45701, OH, United States.
Hao ChiClinical Medical College, Southwest Medical University, Luzhou 646000, China.
Qin WangSichuan Provincial Center for Gynecology and Breast Diseases (Gynecology), Affiliated Hospital of Southwest Medical University, Luzhou 646000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) is a common gynecologic tumor and patients with advanced and recurrent disease usually have a poor clinical outcome. Angiogenesis is involved in the biological processes of tumors and can promote tumor growth and invasion. In this paper, we created a signature for predicting prognosis based on angiogenesis-related lncRNAs (ARLs). This provides a prospective direction for enhancing the efficacy of immunotherapy in CESC patients. We screened seven OS-related ARLs by univariate and multivariate regression analyses and Lasso analysis and developed a prognostic signature at the same time. Then, we performed an internal validation in the TCGA-CESC cohort to increase the precision of the study. In addition, we performed a series of analyses based on ARLs, including immune cell infiltration, immune function, immune checkpoint, tumor mutation load, and drug sensitivity analysis. Our created signature based on ARLs can effectively predict the prognosis of CESC patients. To strengthen the prediction accuracy of the signature, we built a nomogram by combining signature and clinical features.

Indexed as

AngiogenesisCESCChemotherapyImmunotherapyLncRNAsPrognostic signature

Identifiers

PMID38706901
PMCPMC11064265

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.